UnknownNot applicableNCT05164978

DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH

Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing Friendship Hospital
Principal Investigator
Zhao Wang, m.d
Beijing Friendship Hospital
Intervention
DEP combine with PD-1 antibody(drug)
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
20212023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05164978 on ClinicalTrials.gov

Other trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Additional recruiting or active studies for the same condition.

See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

← Back to all trials